$BABY (Natus Medical Inc.)

$BABY {{ '2016-09-26T12:18:03+0000' | timeago}} • Announcement

$BABY has agreed to acquire GN Otometrics business from GN Store Nord in an all cash transaction for $145MM. The transaction is expected to close by the end of 2016. Otometrics is a manufacturer of hearing diagnostics and balance assessment equipment, disposables & software, with an annual revenue of approx. $110MM.

$UNH {{ '2018-01-16T17:58:43+0000' | timeago}} • Infographic

$UNH UnitedHealth Group Incorporated Earnings AlphaGraphic: Q4 2017 Highlights

$MDT {{ '2018-01-16T17:16:57+0000' | timeago}} • Announcement

$MDT received FDA clearance of the Riptide Aspiration System, adding a valuable tool to the Acute Ischemic Stroke (AIS) product portfolio. This is designed to retrieve thrombus (or blood clot) through the Arc Catheter and restore blood flow in patients experiencing blockage of an artery in the brain, known as an ischemic stroke.

$MDT {{ '2018-01-10T14:44:35+0000' | timeago}} • Announcement

The FDA has approved an innovative clinician programmer for the SynchroMed-II Intrathecal Drug Delivery system developed by medical technology company $MDT, for chronic pain and spasticity. SynchroMed-II, an implantable pump, delivers medication directly to the fluid around the spinal cord. It is an app that facilitates simple, guided workflows.

$SYK {{ '2018-01-09T17:21:37+0000' | timeago}} • Announcement

$SYK said that for 4Q17 its preliminary results are of net sales growth of 10% to $3.5Bil, while for FY17, its net sales grew 9.9% to $12.4Bil. Excluding the impact of foreign currency & acquisitions, net sales rose 8.1% and 7.1% in 4Q17 and FY17. For 2018, $SYK expects modest headwinds that will be manageable within its overall financial targets.

$HRC {{ '2018-01-09T17:07:14+0000' | timeago}} • Announcement

$HRC announced its preliminary 1Q18 revenue. For this period, the company expects worldwide revenue of approx $670MM, an increase of 5% YoY. Core revenue increased approx 2%, exceeding the company's previously issued guidance of flat core revenue growth.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$BABY {{ '2018-01-08T12:48:13+0000' | timeago}} • Announcement

$BABY said that for FY18, the company expects revenue of $535-540MM and non-GAAP EPS of $1.60-1.65. For 1Q18, the company expects revenue of $125-127MM and non-GAAP EPS of $0.23-0.24. For 4Q17, $BABY expects to report revenue of approx. $131-132MM, while for FY17 revenue is expected to be $500.5-501.5MM.

$BABY {{ '2018-01-05T14:35:34+0000' | timeago}} • Announcement

$BABY appointed Leslie McDonnell as VP and General Manager of its Newborn Care Business Unit. McDonnell will report to CEO Jim Hawkins, and will be responsible for leading and expanding Natus' newborn care business. McDonnell is expected to join Natus on Feb. 12, 2018.

$BABY {{ '2018-01-05T14:07:05+0000' | timeago}} • Announcement

$BABY has named Leslie McDonnell as Vice President and General Manager of its Newborn Care Business Unit. Ms. McDonnell will report to Jim Hawkins, CEO. She is expected to join $BABY on February 12, 2018.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$ABBV {{ '2017-12-21T13:23:43+0000' | timeago}} • Announcement

$ABBV announced positive top-line results from the Phase 3 SELECT-MONOTHERAPY clinical trial. Upadacitinib is not approved by regulatory authorities and its safety and efficacy have not been established.

$ZBH {{ '2017-12-19T14:31:26+0000' | timeago}} • Announcement

$ZBH appointed Bryan Hanson as President and CEO and a member of the BoD, effective Dec. 19, 2017. Daniel Florin, who has served as Interim CEO since July 11, 2017, will continue in his role as SVP and CFO. Most recently, Hanson served as a $MDT's Executive Committee member and as EVP and President of Medtronic's Minimally Invasive Therapies Group.

$MDT {{ '2017-12-19T14:11:39+0000' | timeago}} • Announcement

$MDT has named Bob White, previously SVP and President of APAC Region, as EVP and President of Minimally Invasive Therapies Group. The company also announced Chris Lee, SVP and President of Greater China Region, will assume the position of APAC Region President. These leadership changes are effective immediately.

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

$AGN {{ '2017-12-18T22:14:14+0000' | timeago}} • Announcement

$AGN and its development partner Gedeon Richter Plc reported positive results from phase 3 study of cariprazine, which is used to treat the bipolar depression. Allergan plans to file the New Drug Application to the FDA in 2H18.

$IPXL {{ '2017-12-18T13:05:53+0000' | timeago}} • Announcement

Amneal Pharmaceuticals LLC and $IPXL said Robert Stewart will join Amneal as President, effective Jan. 25, 2018. Stewart most recently served as COO of $AGN. After completion of combination of Amneal and $IPXL, Stewart will become President and CEO of the combined company, to be named Amneal Pharmaceuticals Inc., and will become a BoD member.

$CNMD {{ '2017-12-14T12:14:54+0000' | timeago}} • Announcement

$CNMD said it will begin trading ex-dividend on Dec. 14, 2017. The company's BoD declared a cash dividend of $0.2 per share that is scheduled to be paid on Jan. 5, 2018. This is the 17th quarter that the company has paid the same dividend.

$AGN {{ '2017-12-12T19:58:45+0000' | timeago}} • Announcement

$AGN gets FDA clearance for the CoolSculpting, a treatment to improve the appearance of lax tissue in double chin. Allergan got this CoolSculpting technology by acquiring Zeltiq Aesthetics in Feb. 2017 for $2.4Bil. Allergan added that in an 18-week study, 77% of patients showed improved appearance in their lax tissue.

$AGN {{ '2017-12-12T19:07:05+0000' | timeago}} • Announcement

$AGN enters into a buyout deal with $RPRX through a cash tender offer of $0.67 per share, representing a 43% premium of Repros Therapeutics’ Dec. 11th closing price ($0.47). Allergan's subsidiary will acquire Repros, which focuses on developing the drugs for male and female reproductive disorders. The deal is expected to close in 1Q18.

Recent Transcripts

IMUC (ImmunoCellular Therapeutics, Ltd.)
Tuesday, November 21 2017 - 10:00pm
MDT (Medtronic plc)
Tuesday, November 21 2017 - 1:00pm
BTX (BioTime, Inc.)
Thursday, November 9 2017 - 9:30pm
RMTI (Rockwell Medical, Inc.)
Wednesday, November 8 2017 - 9:30pm
ELMD (Electromed, Inc.)
Wednesday, November 8 2017 - 2:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
IRIX (IRIDEX Corporation)
Thursday, November 2 2017 - 9:00pm
CNMD (CONMED Corporation)
Thursday, November 2 2017 - 8:30pm
ZTS (Zoetis Inc.)
Thursday, November 2 2017 - 12:30pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, November 2 2017 - 12:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
MASI (Masimo Corporation)
Tuesday, October 31 2017 - 8:30pm
ABBV (AbbVie Inc.)
Friday, October 27 2017 - 1:00pm
SYK (Stryker Corporation)
Thursday, October 26 2017 - 8:30pm
VAR (Varian Medical Systems, Inc.)
Wednesday, October 25 2017 - 9:00pm
BABY (Natus Medical Inc.)
Wednesday, October 25 2017 - 3:00pm
NURO (NeuroMetrix Inc.)
Thursday, October 19 2017 - 12:00pm
UNH (UnitedHealth Group Incorporated)
Tuesday, October 17 2017 - 12:45pm
ELMD (Electromed, Inc.)
Wednesday, September 6 2017 - 1:00pm
IMUC (ImmunoCellular Therapeutics, Ltd.)
Wednesday, August 23 2017 - 9:00pm

AlphaGraphics you may like